Doug Berthiaume to Retire as Chairman of the Board of Waters Corporation

Chris O'Connell Elected as New Chairman

23-Oct-2017 - USA

Waters Corporation announced that Douglas A. Berthiaume will retire as Chairman of the Board of Directors of the Company, effective December 31, 2017. The Board of Directors has elected Christopher J. O'Connell, President and Chief Executive Officer, as its new Chairman effective January 1, 2018.

Thomas P. Salice will continue to serve as the Company's Independent Lead Director.

Commenting on the announcement, Mr. Berthiaume said, "It has been my pleasure to serve as both an executive and non-executive Chairman of the Board of Directors of Waters. Two years ago, upon my retirement as Chief Executive Officer, Chris O'Connell assumed the CEO position and has very successfully guided the Company to new levels of growth and profitability. I am very pleased to once again pass the torch to Chris as he assumes the additional role of Chairman of the Board in addition to his service as CEO of the company."

“I am honored to have been elected as Waters' new Chairman of the Board of Directors," said Christopher J. O'Connell. "For 20 years as an independent public company, Waters' success was guided by Doug Berthiaume's visionary leadership. I am truly grateful to Doug for his strong support of me and the Waters team over the past two years. Speaking on behalf of all Waters employees worldwide, I wish Doug the very best as he completes his transition to retirement."

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Horizon Discovery and Fox Chase Cancer Center announce collaboration to apply rAAV gene targeting in mouse embryonic stem cells and research into EGFR-therapy resistance. - Collaboration will establish a new Center Of Excellence in Mammalian Gene Editing

Hybrigenics receives first patent grant on chemical inhibitors of Ubiquitin-Specific Proteases

Aastrom Biosciences and Zellera AG Announce the Initiation of a Clinical Trial for Bone Grafting in Spain - Aastrom's Proprietary TRCs to be Utilized in Second European Clinical Study to Treat Major Bone Fractures

Movetis Announces Start of a Phase IIa trial for M0002 in Ascites

Addex Achieves Second Milestone in Parkinson's Disease Collaboration with Merck & Co., Inc. - Data Confirm Non-Dopaminergic Approach to Treating Parkinson's Disease

BioInvent extends antibody collaboration with Japanese pharmaceutical partner - Lead candidate for inflammation to progress into preclinical development

Orexo's stock market move sends positive signal for biotech industry

PerkinElmer, Inc. and Corning Incorporated Announce Strategic Collaboration for the Advancement of Label-Free Technologies - Strategic agreement to develop next-generation platforms for Life Sciences research

Oxford BioTherapeutics Appoints Michael Moore as Chairman

Lundbeck enters into drug discovery collaboration with Zenobia and Vernalis

YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with brain cancer

M&A - The trials and tribulations - Former Schering & Plough CEO speaks out about the pharmaceutical Industry. Where they went wrong and the solutions, which lead to the successful sale